A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

ClinicalTrials.gov ID: NCT07210723

Public ClinicalTrials.gov record NCT07210723. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 29, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Study identification

NCT ID: NCT07210723
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Kardigan, Inc.; Industry
Enrollment: 332 participants

Conditions and interventions

Conditions

Symptomatic Genetic Dilated Cardiomyopathy

Interventions

Placebo Drug
danicamtiv Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 12, 2026
Primary completion: Aug 31, 2027
Completion: Dec 31, 2027
Last update posted: Apr 27, 2026

2026 – 2028

United States locations

U.S. sites: 14
U.S. states: 13
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of Alabama Birmingham	Birmingham	Alabama	35233	Recruiting
Cedars Sinai	Los Angeles	California	90048	Recruiting
UCSF	San Francisco	California	94158	Recruiting
MedStar Washington Hospital Center	Washington D.C.	District of Columbia	20010	Recruiting
Louisiana State University (LSU) Health Sciences Center	New Orleans	Louisiana	70112	Recruiting
Brigham and Women's Hospital	Boston	Massachusetts	02115	Recruiting
Henry Ford Health System	Detroit	Michigan	48202	Recruiting
Mayo Clinic Rochester	Rochester	Minnesota	55905	Recruiting
Washington University in St. Louis	St Louis	Missouri	63110	Recruiting
University of Nebraska Medical Center	Omaha	Nebraska	68106	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
The Ohio State University Wexner Medical Center	Columbus	Ohio	43210	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
Baylor College of Medicine	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07210723, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 27, 2026 · Synced Apr 29, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07210723 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →